Delivery Order SPE2DR25D1051-SPE2DR26F38F8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,194.48 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pens on December 9, 2025, with an ultimate completion date of December 10, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,019.57 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pens on October 27, 2025, with completion targeted for October 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $14,518.84 delivery order to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pens on July 15, 2025, with completion scheduled for July 16, 2025. This competitive award carries firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Zepbound 15 mg/0.5 mL pens with a ceiling value of $17,362.88. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.9 million through December 2026. The product will be performed at AmerisourceBergen's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $8,745.36 firm fixed-price delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for the supply of Zepbound 5 mg/0.5 ml pens. The contract, which has no set-aside designation, is scheduled for completion by December 2, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 5 mg/0.5 mL pens valued at $3,050.32 with a completion date of August 18, 2025. This is a firm fixed-price delivery order with no set-aside designation, executed under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $3,053.36 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on November 25, 2025, with completion expected by November 26, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance fulfillment at AmerisourceBergen's Conshohocken, Pennsylvania facility. The contract is a child order issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $2,415.70 firm fixed price delivery order to AmerisourceBergen Drug Corp on October 31, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens with a completion date of November 3, 2025. This competitively awarded, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The delivery location is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Zepbound 12.5 mg/0.5 mL pens at a ceiling value of $1,525.20. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with performance to be completed by July 1, 2025, with fulfillment occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order falls under the company's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a $30,444.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pens on November 18, 2025, with completion scheduled for November 19, 2025. This non-set-aside competitive award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement valued through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- SPE2DR25D1051Indefinite Delivery Contract
- SPE2DR25D1051-SPE2DR26F38F8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,058.35 to AmerisourceBergen Drug Corp for the supply of Zepbound 12.5 mg/0.5 mL pens on December 4, 2025, with completion expected by December 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government healthcare entities. The company's extensive portfolio of federal contracts demonstrates its capacity to supply a comprehensive range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This specific delivery order for Zepbound, a diabetes medication, reflects the company's established role as a primary supplier within the DLA's global pharmaceutical support network, which is transitioning toward a new Pharmaceutical Prime Vendor Global Program Generation V contracting approach designed to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.1k | 12/3/25 |